New York State Teachers Retirement System Has $28.01 Million Position in DexCom, Inc. (NASDAQ:DXCM)

New York State Teachers Retirement System decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 360,161 shares of the medical device company's stock after selling 6,147 shares during the quarter. New York State Teachers Retirement System owned about 0.09% of DexCom worth $28,010,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in DXCM. Versant Capital Management Inc acquired a new position in shares of DexCom during the 4th quarter worth approximately $25,000. Riverview Trust Co increased its holdings in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after acquiring an additional 232 shares during the last quarter. Heck Capital Advisors LLC acquired a new position in shares of DexCom during the 4th quarter worth approximately $38,000. RPg Family Wealth Advisory LLC acquired a new position in shares of DexCom during the 3rd quarter worth approximately $57,000. Finally, Covestor Ltd increased its holdings in shares of DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company's stock worth $64,000 after acquiring an additional 335 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the company's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares of the company's stock, valued at $23,347,850.04. This represents a 0.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,083 shares of company stock worth $3,309,794 in the last ninety days. 0.30% of the stock is owned by insiders.

DexCom Price Performance

Shares of DXCM stock traded down $0.85 on Wednesday, hitting $89.68. 3,217,213 shares of the company's stock were exchanged, compared to its average volume of 3,632,234. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a market cap of $35.03 billion, a P/E ratio of 62.71, a price-to-earnings-growth ratio of 2.31 and a beta of 1.14. The company has a 50 day moving average of $82.65 and a 200 day moving average of $75.62.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts predict that DexCom, Inc. will post 1.98 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on DXCM shares. Leerink Partners decreased their target price on DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Wells Fargo & Company boosted their target price on DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Finally, Sanford C. Bernstein upped their price objective on DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $99.06.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.